Novo Nordisk (NVO) PT Lowered to $40 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mail
Get Alerts NVO Hot Sheet
Rating Summary:
8 Buy, 16 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 14
Join SI Premium – FREE
BMO Capital analyst Evan Seigerman lowered the price target on Novo Nordisk (NYSE: NVO) to $40.00 (from $47.00) while maintaining a Market Perform rating.
The analyst commented: "Challenging 3Q25 comparator and eroding US market share are likely to temper Ozempic revenue in the quarter. As a reminder in 3Q25 Novo benefited from a DKK 2B gross-to-net benefit. A large portion of this benefit was tied to Ozempic, increasing revenue for the quarter (DKK reported revenue of 30.7B). This gross-to-net benefit is likely to exaggerate YoY declines for Ozempic in the US in 3Q26."
You May Also Be Interested In
- Pegasystems (PEGA) PT Lowered to $43 at Rosenblatt
- BankUnited (BKU) PT Lowered to $48 at Raymond James
- KeyCorp (KEY) PT Raised to $27 at DA Davidson on Solid Quarter
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
BMO Capital, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
